A Phase 1, Multicenter, Randomized, Double-blind, Placebo-controlled, Single and Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CC-90005 in Healthy Subjects and Subjects With Moderate to Severe Plaque-type Psoriasis

Trial Profile

A Phase 1, Multicenter, Randomized, Double-blind, Placebo-controlled, Single and Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CC-90005 in Healthy Subjects and Subjects With Moderate to Severe Plaque-type Psoriasis

Discontinued
Phase of Trial: Phase I

Latest Information Update: 16 Feb 2016

At a glance

  • Drugs CC 90005 (Primary)
  • Indications Plaque psoriasis
  • Focus Adverse reactions
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 08 Feb 2016 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 11 Sep 2015 Planned number of patients changed from 72 to 80, as reported by ClinicalTrials.gov.
    • 28 Jul 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top